Trial Watch-Oncolytic viruses and cancer therapy

Jonathan Pol¹, Aitziber Buqué¹, Fernando Aranda², Norma Bloy¹, Isabelle Cremer³, Alexander Eggermont⁴, Philippe Erbs⁵, Jitka Fucikova⁶, Jérôme Galon⁷, Jean-Marc Limacher⁵, Xavier Preville⁵, Catherine Sautès-Fridman³, Radek Spisek⁶, Laurence Zitvogel⁸, Guido Kroemer⁹, Lorenzo Galluzzi¹

Affiliations

¹ INSERM, U1138, Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie/Paris VI, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France.
² Group of Immune receptors of the Innate and Adaptive System, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS) , Barcelona, Spain.
³ INSERM, U1138, Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie/Paris VI, Paris, France; Equipe 13, Center de Recherche des Cordeliers, Paris, France.
⁴ Gustave Roussy Cancer Campus , Villejuif, France.
⁵ Transgene S.A. , Illkirch-Graffenstaden, France.
⁶ Sotio, Prague, Czech Republic; Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic.
⁷ INSERM, U1138, Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie/Paris VI, Paris, France; Laboratory of Integrative Cancer Immunology, Centre de Recherche des Cordeliers, Paris, France.
⁸ Gustave Roussy Cancer Campus, Villejuif, France; INSERM, U1015, CICBT507, Villejuif, France.
⁹ INSERM, U1138, Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie/Paris VI, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France; Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.

PMID: 27057469
PMCID: PMC4801444
DOI: 10.1080/2162402X.2015.1117740

Review

Trial Watch-Oncolytic viruses and cancer therapy

Jonathan Pol et al. Oncoimmunology. 2015.

. 2015 Dec 8;5(2):e1117740.

doi: 10.1080/2162402X.2015.1117740. eCollection 2016 Feb.

Authors

Affiliations

¹ INSERM, U1138, Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie/Paris VI, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France.
² Group of Immune receptors of the Innate and Adaptive System, Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS) , Barcelona, Spain.
³ INSERM, U1138, Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie/Paris VI, Paris, France; Equipe 13, Center de Recherche des Cordeliers, Paris, France.
⁴ Gustave Roussy Cancer Campus , Villejuif, France.
⁵ Transgene S.A. , Illkirch-Graffenstaden, France.
⁶ Sotio, Prague, Czech Republic; Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic.
⁷ INSERM, U1138, Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie/Paris VI, Paris, France; Laboratory of Integrative Cancer Immunology, Centre de Recherche des Cordeliers, Paris, France.
⁸ Gustave Roussy Cancer Campus, Villejuif, France; INSERM, U1015, CICBT507, Villejuif, France.
⁹ INSERM, U1138, Paris, France; Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie/Paris VI, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France; Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.

PMID: 27057469
PMCID: PMC4801444
DOI: 10.1080/2162402X.2015.1117740

Abstract

Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that selectively infect and kill malignant cells while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. During the past few years, great efforts have been dedicated to the development of oncolytic viruses with improved specificity and potency. Such an intense wave of investigation has culminated this year in the regulatory approval by the US Food and Drug Administration (FDA) of a genetically engineered oncolytic viral strain for use in melanoma patients. Here, we summarize recent preclinical and clinical advances in oncolytic virotherapy.

Keywords: Cavatak™; GM-CSF; JX-594; ONCOS-102; Reolysin®; talimogene laherparepvec.

PubMed Disclaimer

References

1. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658-70; PMID:22781695; http://dx.doi.org/ 10.1038/nbt.2287 - DOI - PMC - PubMed
1. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254:178-216; PMID:17383089; http://dx.doi.org/ 10.1016/j.canlet.2007.02.002 - DOI - PMC - PubMed
1. Walther W, Schlag PM. Current status of gene therapy for cancer. Curr Opin Oncol 2013; 25:659-64; PMID:24100345; http://dx.doi.org/ 10.1097/CCO.0000000000000004 - DOI - PubMed
1. Bell J, McFadden G. Viruses for tumor therapy. Cell Host Microbe 2014; 15:260-5; PMID:24629333; http://dx.doi.org/ 10.1016/j.chom.2014.01.002 - DOI - PMC - PubMed
1. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014; 14:559-67; PMID:24990523; http://dx.doi.org/ 10.1038/nrc3770 - DOI - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Trial Watch-Oncolytic viruses and cancer therapy

Affiliations

Trial Watch-Oncolytic viruses and cancer therapy

Authors

Affiliations

Abstract

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous